News
Researchers conducted the ACHIEVE-1 trial to assess the effect of orfoglipron on glycemic control among patients with early-stage type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback